Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Polyneuron
1515
Polyneuron
Health Care
Technology
Biotechnology
Medical
Pharmaceuticals
Swiss biotech start-up. We’re using our Antibody-Catch® technology to develop the most accurate treatment of rare autoimmune disorders.
Suggest edits
Type
B2b
Founded
2014
Raised
$41M
Follow us
Companies in the same industry
Laboratoires Majorelle
Aura Biosciences
EnBiotix, Inc.
Spiral Therapeutics
Prometic
Hazel Technologies
Hercules Pharmaceuticals, Inc.
Palleon Pharmaceuticals
Camallergy
Ironwood Pharma
Alexa global traffic share
Twitter followers
Overview
Funding
4
Add info
Latest funding
Show all
$15,281,700
Venture capital (Series A) - 2020
Sofinnova Partners
New Enterprise Associates
HBM Healthcare Investments AG
$22,600,000
Venture capital (Series A) - 2019
Sofinnova Partners
New Enterprise Associates
Team Size
1–10
Employees
I work here
Location
Switzerland
Headquarters
Explore Switzerland
$15,281,700
Venture capital (Series A)
FinSMEs
Polyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M
$22,600,000
Venture capital (Series A)
PE HUB
Swiss biotech company Polyneuron inks funding
$3,109,641
Seed fund
FinSMEs
Polyneuron Pharmaceuticals Completes CHF3.1M in Seed Financing
Health
Seed fund
startupticker
Polyneuron Pharmaceuticals closes CHF 3 Million seed financing round.ch | The Swiss Startup News channel
Health
Funding
